About UniversitätsSpital Zürich; Zentrum für Hämatologie und Onkologie, Klinik für Onkologie
"Die Klinik für Medizinsche Onkologie und Hämatologie am USZ Campus ist spezialisiert auf die Diagnostik und Behandlung von Tumorerkrankungen aller Organsysteme. Ebenso diagnostizieren und behandeln die Klinik gutartige Veränderungen des Blutes und des Blutgerinnungssystems. Dank moderner Analysetechnik können wir präzise Diagnosen erstellen und personalisierte Therapien anbieten."
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Hoffmann-La Roche
19
Gilead Sciences
2
Alliance Foundation Trials, LLC.
1
Celgene
1
Celgene Corporation
1
Clinical Trials at UniversitätsSpital Zürich; Zentrum für Hämatologie und Onkologie, Klinik für Onkologie
During the past decade, UniversitätsSpital Zürich; Zentrum für Hämatologie und Onkologie, Klinik für Onkologie conducted 14 clinical trials. In the 10-year time frame, 14 clinical trials started and 12 clinical trials were completed, i.e. on
average, 85.7% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 3 clinical trials were completed. i.e. 37.5%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Efficacy and Safety Study of CC-5013 Monotherapy in Subjects With Myelodysplastic Syndromes
2003-06-01
2007-02-01
Completed
215
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
2006-09-04
2011-05-26
Completed
545
A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma
2007-07-26
2011-11-30
Terminated
787
A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)
2011-07-26
2018-01-31
Terminated
1,418
Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma
2011-03-01
2014-07-31
Completed
74
A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous Rituximab
2011-12-20
2018-06-02
Completed
692
A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
2014-01-22
2019-01-11
Completed
667
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants
2014-08-19
2026-09-29
Active, not recruiting
303
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "UniversitätsSpital Zürich; Zentrum für Hämatologie und Onkologie, Klinik für Onkologie" #1 sponsor was "Hoffmann-La Roche" with 19 trials, followed by "Gilead Sciences" with 2 trials
sponsored, "Alliance Foundation Trials, LLC." with 1 trials sponsored, "Celgene" with 1 trials sponsored and "Celgene Corporation"
with 1 trials sponsored. Other sponsors include -5 different institutions and
companies that sponsored additional 5 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "UniversitätsSpital Zürich; Zentrum für Hämatologie und Onkologie, Klinik für Onkologie"
#1 collaborator was "AbbVie" with 1 trials as a collaborator, "Austrian Breast & Colorectal Cancer Study Group" with 1 trials as a collaborator, "Breast International Group" with 1 trials as a collaborator, "Everest Medicines" with 1 trials as a collaborator and "Fondazione Italiana Linfomi ONLUS" with 1 trials as a collaborator. Other collaborators include 1 different institutions and companies that were
collaborators in the rest 11 trials.
Clinical Trials Conditions at UniversitätsSpital Zürich; Zentrum für Hämatologie und Onkologie, Klinik für Onkologie
According to Clinical.Site data, the most researched conditions in "UniversitätsSpital Zürich; Zentrum für Hämatologie und Onkologie, Klinik für Onkologie" are
"Non-Small Cell Lung Cancer" (3 trials), "Myelodysplastic Syndromes" (2 trials), "Non-Hodgkin's Lymphoma" (2 trials), "Adenocarcinoma" (1 trials) and "B-cell Lymphoma" (1 trials). Many other conditions were trialed in "UniversitätsSpital Zürich; Zentrum für Hämatologie und Onkologie, Klinik für Onkologie" in a lesser frequency.
Clinical Trials Intervention Types at UniversitätsSpital Zürich; Zentrum für Hämatologie und Onkologie, Klinik für Onkologie
Most popular intervention types in "UniversitätsSpital Zürich; Zentrum für Hämatologie und Onkologie, Klinik für Onkologie" are "Drug" (24 trials), "Biological" (2 trials) and "Other" (1 trials). Other intervention types were less common.
The name of intervention was led by "Atezolizumab" (8 trials), "Carboplatin" (6 trials), "Cisplatin" (5 trials), "Paclitaxel" (5 trials) and "Gemcitabine" (4 trials). Other intervention names were less common.
Clinical Trials Genders at UniversitätsSpital Zürich; Zentrum für Hämatologie und Onkologie, Klinik für Onkologie
The vast majority of trials in "UniversitätsSpital Zürich; Zentrum für Hämatologie und Onkologie, Klinik für Onkologie" are
23 trials for "All" genders and 1 trials for "Male" genders.
Clinical Trials Status at UniversitätsSpital Zürich; Zentrum für Hämatologie und Onkologie, Klinik für Onkologie
Currently, there are NaN active trials in "UniversitätsSpital Zürich; Zentrum für Hämatologie und Onkologie, Klinik für Onkologie".
undefined are not yet recruiting,
4 are recruiting,
8 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 9 completed trials in UniversitätsSpital Zürich; Zentrum für Hämatologie und Onkologie, Klinik für Onkologie,
undefined suspended trials,
and 3 terminated clinical trials to date.
Out of the total trials that were conducted in UniversitätsSpital Zürich; Zentrum für Hämatologie und Onkologie, Klinik für Onkologie, 1 "Phase 1"
clinical trials were conducted, 6 "Phase 2" clinical
trials and 17 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 1 trials, and there were
also 0 trials that are defined as “Not Applicable".